Why Aeglea BioTherapeutics Stock Is Way Down Today
Shares of Aeglea BioTherapeutics (NASDAQ: AGLE), a clinical-stage biopharmaceutical company, are falling today in response to mixed clinical-trial data. Investors nervous about the future of the company's lead candidate pushed the stock 36.6% lower as of 11:53 a.m. ET on Monday.
Aegla BioTherapeutics' lead candidate, pegzilarginase, is an enzyme replacement therapy for patients with an ultra-rare amino-acid metabolism disorder called arginase 1 deficiency. The trial reached its primary endpoint by dramatically reducing circulating arginine by 80% compared to baseline measurements.
Image source: Getty Images.
Source Fool.com
